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ABSTRACT 
Objective: Mild Behavioral Impairment (MBI) is a neurobehavioural syndrome 
characterized by later life emergent neuropsychiatric symptoms (NPS) which 
represent an at-risk state for incident cognitive decline and dementia in people with 
Mild Cognitive Impairment.  We undertook a study to determine whether MBI was 
associated with progressive changes in neuropsychological performance in people 
without significant cognitive impairment. 
 
Methods: 9,931 older adults enrolled in the PROTECT study who did not have MCI 
or dementia undertook a comprehensive neuropsychological battery measuring 
attention, reasoning, executive function and working memory at baseline and one 
year.  MBI was ascertained using self-administration of the MBI-C at one year, and 
participants grouped according to MBI status: no symptoms, intermediate 
neuropsychiatric symptoms and MBI.  All assessments were completed online and 
data analyzed using MMRM ANOVA. 
 
Results: 949 (10%) people had MBI.  These individuals had significantly worse 
cognitive performance at baseline and significantly greater decline over one year in 
the four composites cognitive scores measuring attentional intensity 
(F(2,8578)=3.97,p=0.019), sustained attention (F(2,8578)=18.63, p<.0001), 
attentional fluctuation (F(2,8578)=10.13, p=<.0001) and working memory 
F(2,9895)=13.1, p<.0001. 
 
Conclusions: Our novel findings show that MBI is associated with faster decline in 
attention and working memory in this cognitively normal sample. MBI may be an earlier 
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marker of neurodegenerative disease than MCI, captured at the stage of SCD or 
before, raising the possibility that MBI represents a novel target for dementia clinical 
trials or prevention strategies.   
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OBJECTIVE 
 
Dementia, the most common cause of which is Alzheimer’s disease (AD), affects an 
estimated 45 million people and is a leading cause of morbidity and death; it has 
devastating impact on people with the disease and those caring for them and costs 
the world economy around US $818 billion per year (1). Developing new and more 
effective treatments for AD is an urgent priority however there have been no new 
licensed pharmacologic therapies for 15 years (2).  As such there is an increasing 
realization of the need for improved markers of early identification of people with pre-
clinical AD, and their translation into effective stratification tools and a broader range 
of treatment targets (3, 4).  The identification of a marker which is easily and 
inexpensively detected in the general population, and whose cognitive correlates could 
be measured over the short term, would represent a major step change towards 
reaching this goal.  There is an increasing evidence base that later life emergent and 
persistent neuropsychiatric symptoms (NPS), known as Mild Behavioral Impairment 
(MBI) (4),  may be one such maker. 
 
MBI is a neurobehavioral syndrome characterized by the onset of new and sustained 
NPS in later life (5). For some individuals, MBI may be an early manifestation of 
neurodegenerative disease in advance of significant cognitive impairment.  MBI 
consists of five domains: impaired drive and motivation (apathy) (6); emotional 
dysregulation (mood and anxiety symptoms) (7); impulse 
dyscontrol/agitation/abnormal reward salience (changes in response inhibition and 
self-regulation); social inappropriateness (impaired social cognition) (8); and abnormal 
thoughts/perception (psychosis) (9), assessed individually and collectively for their 
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impact on cognition.  Importantly, MBI explicitly excludes psychiatric illness a priori, 
and mandates that NPS be emergent in later life, and sustained for 6-months.  
 
Recently, the International Society to Advance Alzheimer’s Research and Treatment 
(ISTAART)-Alzheimer’s Association (AA), NPS Professional Interest Area published 
research diagnostic criteria for MBI, which described explicitly the relationship 
between MBI and MCI, and generated the five MBI domains for further study (10).  
Subsequently, the Mild Behavioral Impairment Checklist (MBI-C) was developed to 
reflect these new criteria and capture these symptoms in preclinical populations with 
the goal of operationalizing the assessment of the MBI criteria and to serve as a case 
ascertainment tool (11).  It thus provides an inexpensive method for capturing a 
population at higher risk for cognitive decline and dementia. 
 
There is abundant evidence from longitudinal cohort studies that MBI, or more broadly 
NPS, in the context of Mild Cognitive Impairment (MCI) is associated with a greater 
risk of dementia than MCI without NPS (12-16). In addition, MBI is associated with a 
significantly faster rate of cognitive decline and progression to dementia than late life 
psychiatric illness (17), emphasizing the importance and utility of this syndrome for 
detecting this at-risk group. Although not studied using the MBI framework, there is 
also evidence that some NPS, particularly emergent psychosis, are also associated 
with a significantly increased risk of incident MCI and dementia over periods up to 5 
years in individuals with a mean age over 70 (18-23).   
 
The only study to have examined the detailed neuropsychological profile associated 
with MBI did so at a single time point (17).  Widespread impairments across attention, 
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memory, and executive function were observed in the MBI group but 25% of the 
sample had memory impairment, so it likely included some patients with MCI.  The 
profile of neuropsychological impairments associated with MBI in populations with no 
significant cognitive impairment remains unknown and the question of whether subtle 
changes in cognitive performance occur over time in these preclinical groups 
represents an important gap in current understanding.    
 
The aims of this study were to conduct a detailed analysis of the pattern of progressive 
neuropsychological impairments associated with MBI in a large cohort of 9,931 
cognitively normal individuals over the age of 50.  We hypothesized that MBI would be 
present in this group and that, because it represents an at-risk state for dementia, we 
would observe greater declines in cognition over the course of one year compared to 
those without MBI.  
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METHODS 
 
The PROTECT study 
The study was conducted through the Platform for Research Online to Investigate 
Genetics and Cognition in Aging (PROTECT: http://www.protectstudy.org.uk).  
PROTECT is an innovative UK-based  25‐year longitudinal online research study 
which aims to understand the impact of lifestyle, medical and genetic risk factors of 
cognitive health and dementia in older adults. 
 
Participants 
Participants volunteered to take part in the study by responding to local and national 
publicity, which included radio, print media, Join Dementia Research and invitations to 
persons registered for existing research studies at the Institute of Psychiatry, 
Psychology and Neuroscience at King’s College London.  Inclusion criteria for 
PROTECT enrollment are: 1) age 50 or over; 2) regular access to a computer and the 
internet; and 3) no diagnosis of dementia.  There were no exclusion criteria.  
Volunteers were prospectively recruited from November 2015 through both local and 
national publicity. PROTECT is an ongoing study and as such a data freeze was 
implemented in March 2017 with data extracted for volunteers who had completed 
baseline and 1 year assessments extract. Ethical approval was granted through the 
London Bridge National Research Ethics Committee (reference: 13/LO/1578) and 
informed consent obtained for all participants.  This study is an analysis of the newly 
generated baseline and 1 year data from the PRTOECT study.  
 
Procedure  
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Participants completed a range of online assessments and questionnaires, those 
pertinent to this paper are demographics, a mental health questionnaire and IQCODE 
(included as a supplementary measure of subjective cognitive decline) (24) – all 
completed at baseline - and the MBI-C (completed at 1 year).  Core aspects of 
cognitive function were assessed via two cognitive test batteries; the CogTrackTM 
System (25, 26) and the PROTECT Cognitive Test System (PCTS) (27, 28).  Cognition 
was assessed at baseline and one year with participants being invited to complete 
both test systems.  The PCTS was mandatory and CogTrackTM was optional.  Most 
participants completed both (Table 1). Participants were instructed to complete up to 
three test sessions of each system.  These repeats had to be completed within seven 
days with at least 24 hours between each session.  This design feature was 
implemented in order to overcome familiarization effects, which can influence cognitive 
test data (29, 30).  
 
Assessment of MBI 
 
MBI was rated using the Mild Behavioral Impairment Checklist (MBI-C); a scale 
developed specifically for functionally independent community dwelling older adults, 
with language that reflects NPS in this context, as opposed to the dementia-focused 
language of traditional NPS rating scales used. The MBI-C is a simple and easy to 
administer NPS rating scale taking ~5-7 minutes to complete (by patient, informant, or 
clinician), is scalable to large community cohorts, and is free for use in the public 
domain (available at www.MBItest.org) in several languages (11).  The MBI-C 
comprises 34 questions. Symptoms must be present for at least 6 months 
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(continuously, or intermittently) and must represent a change from a longstanding 
pattern of behavior. Each question is answered “Yes” or “No”, and if “Yes” the item is 
rated according to severity: 1 = mild (noticeable, but not a significant change); 2 = 
moderate (significant, but not a dramatic change); 3 = severe (very marked or 
prominent, a dramatic change). The MBI-C allows for the generation of an overall 
score based on severity responses, thus possible scores range from 0 to 102.  MBI 
diagnosis was operationalized using a cut point on the MBI-C total score of >8, which 
offers good sensitivity and specificity for clinically diagnosed MBI according to the 
ISTAART diagnostic criteria in participants with subjective cognitive decline (31).  We 
further excluded anyone with a history of a psychiatric or neurodevelopmental 
disorder, based on self-report using an online mental health questionnaire to remove 
confounding of the MBI ratings in accordance with the ISTAART-AA MBI criteria (this 
resulted in the further exclusion of 151 people). Finally anyone whose cognitive 
performance was ≥1.5 standard deviations (a level typically associated with MCI) away 
from the norm on 2 or more cognitive domains were excluded; these criteria were 
applied to both baseline measures and on decline over the year minimizing the 
likelihood that there was MCI at baseline and no incident MCI in the sample.  To allow 
for additional sensitivity in our analysis we also split the <8 group in two, creating three 
groups in total: total MBI-C score of 0, “No symptoms” (NS); 1-8, “Intermediate NPS” 
(NPS); and >8 “Mild Behavioral Impairment” (MBI). 
 
Assessment of Cognition 
 
The CogTrackTM system 
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The CogTrackTM System is made up of tasks which have been successfully used for 
over 30 years in clinical research – they assess a broad range of cognitive domains 
including information processing, episodic memory, executive control, reasoning and 
attention (25, 26).  Three composite scores measuring Sustained Attention, Attentional 
Fluctuation and Attentional Intensity were derived from factor analysis of the full 
CogTrackTM battery.  Brief descriptions of these are below with a fuller description 
contained in the supplementary material. 
 
The Sustained Attention Index reflects the ability to sustain concentration and is 
comprised of the accuracy scores of the digit vigilance and choice reaction time tasks 
and the number of false alarms in the digit vigilance task. The cognitive attribute that 
this factor identifies is not the power of concentration at any particular instance; rather 
it identifies a separate and independent feature of how well someone is able to keep 
his/her mind on a single task for a prolonged period. 
 
The Attentional Fluctuation Index is comprised of the coefficient of variance for simple 
reaction time, digit vigilance and choice reaction time and captures moment to moment 
fluctuations in attention. 
 
The Attentional Intensity Index is comprised of the speed scores from the simple 
reaction time, digit vigilance and choice reaction time tasks.  In such tasks, speed 
reflects the intensity of concentration at that particular moment, the faster the 
response, the more processes that are being brought to bear upon the task.  This 
measures levels of effortful concentration. 
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PROTECT cognitive test system (PCTS) 
 
The PCTS is comprised of four tasks measuring verbal reasoning, attention and 
working memory (self-ordered search, paired associates learning, digit span and 
verbal reasoning) (27).  One composite Working Memory score was derived from 
factor analysis of this battery (comprised of paired associate learning, self-ordered 
search and digit span).  A full description of the PCTS battery is contained in the 
supplementary material. 
 
IQCODE 
 
The IQCODE scale was included as a supplementary measure of cognitive impairment 
and was tested for association with MBI-C score.  A subset of 6,452 participants whose 
data was analyzed for this study had a project partner complete the IQCODE scale.  
Average IQCODE score was calculated and two groups were created (based on a cut-
point of 3.3, with higher scores meaning greater cognitive impairment (32)).  Self-rated 
IQCODE (33) was also available for 9,821 participants and was analyzed alongside 
the informant-rated scale to assess for bias as the inclusion of a project partner was 
optional.   A full description of the IQCODE is included in the supplementary material. 
 
 
STATISTICAL ANALYSIS  
 
The software package SAS® Version 9.4 was used to analyze the data. As with any 
cognitive tests, it is well documented that familiarity effects can influence the data.  
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Thus the first test session at baseline was excluded from analysis, leaving only those 
people who had completed a minimum of two test sessions at each time point in the 
analysis. The average performance for the second and third cognitive test session at 
baseline and first and second session at 1 year have been considered here for all 
tasks and all participants. A difference score was created by subtracting the baseline 
scores from the year 1 scores and subjected to a one-way Mixed Effect Model Repeat 
Measurement (MMRM) ANCOVA. A main effect was fitted using the MBI grouping (3 
levels: NS (No Symptoms group, MBI-C=0), NPS (Intermediate NPS group; MBI-C=1-
8) and MBI (MBI group >8). Age, gender, education level (six levels: Secondary 
Education (left school at 16 years); Post-Secondary Education (left school at 18 
years); Vocational Qualification; Undergraduate Degree; Post-graduate Degree; 
Doctorate) , and the number of test sessions performed at baseline and one year were 
fitted as covariates. In addition to this as some of the participants had access to brain 
training games on the PROTECT platform the amount of brain training completed was 
also fitted as a covariate.  Mean change adjusted for these covariates is presented as 
least square means (LSMeans) +/- standard error of the mean (sem).  The relationship 
between IQCODE and MBI grouping was analyzed by chi-square test.  Cohen’s d 
effect sizes were also calculated for the difference in score change between MBI 
groups.   
 
  
14 
 
RESULTS 
 
Demographics 
 
CogTrackTM and PCTS were completed by a total of 8,597 and 9,931 participants 
respectively (Table 1).    Mean age (62), gender proportions (around 75% female) and 
education level were similar for both test packages (as expected given the 
considerable overlap in people who completed both test packages), see Table 1.  
 
MBI-C Responses  
 
The frequency of MBI (MBI-C >8) in this sample was 10%. Intermediate NPS (MBI-C 
total score between 1 and 8) were present in 43% of people. 
 
 
Main Effects of Composite Measures of Sustained Attention, Attentional 
Intensity, Attentional Fluctuation and Working Memory 
 
At baseline, performance on all four cognitive composite measures was consistently 
superior for the no symptom group and poorest the MBI group, with the NPS group 
falling in between (Table 2).  
 
Significant main effects of MBI grouping on decline over one year for the groups were 
seen for the Attentional Intensity Index F(2,8578)=3.97,p=0.0189, the Sustained 
Attention Index F(2,8578)=18.63, p<.0001, the Attentional Fluctuation Index 
15 
 
F(2,8578)=10.13, p=<.0001 and the Working Memory Factor F(2,9895)=13.1, 
p<.0001, see Table 3 and Figure 1.   For all four measures, decline in the MBI group 
was greater than in both the intermediate NPS and no symptoms group.  For all 
measures except the Attentional Intensity Index, decline in the NPS group was also 
greater than in the no symptom group. 
 
Main Effects of Individual Cognitive Measures 
 
Baseline performance on individual measures broadly mirrored the composite scores, 
with the MBI group generally performing worse with the exceptions of simple reaction 
time, digit vigilance accuracy and pattern separation (original stimuli) where there were 
no differences in performance (Table 2).  
 
Decline over one year on the following 12 measures was significantly associated with 
MBI: grammatical reasoning accuracy (F(2,8561)=12.14, p<.0001), simple reaction 
time coefficient of variance (CV) (F(2,8586)=6.52, p=.0015), digit vigilance accuracy 
(F(2,8585)=9.06, p=.0001), digit vigilance speed (F(2,8585)=12.14, p=.0006), digit 
vigilance false alarms (F(2,8585)=11.63, p<.0001), digit vigilance CV (F(2,8585)=11.7, 
p<.0001), choice reaction time accuracy (F(2,8579)=7.55, p=.0005), choice reaction 
time speed (F(2,8579)=3.43, p=.0324), choice reaction time CV (F(2,8579)=3.53, 
p<.0295), paired associate learning (F(2,9919)=5.09, p=.0062), self-ordered search 
(F(2,9895)=18.96, p<0.0001) and verbal reasoning (F(2,9909)=3.62, p=.0269).   The 
seven tests that did not reach statistical significance were grammatical reasoning 
speed, simple reaction time speed, all four pattern separation tests and digit span 
(Supplementary table 3). 
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IQCODE  
IQCODE ratings were available for 6,452 participants.  A significant relationship was 
identified between the MBI grouping and the IQCODE grouping (Χ2 (2)=116.98, 
p<.0001), with higher proportions of high IQCODE scores among participants with MBI 
(Table 4).  Self-rated IQCODE showed the same pattern (Χ2 (2)=652.97, p<.0001). 
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CONCLUSIONS 
 
This is the first study to show a clear and measurable pattern of decline in attention 
and working memory over one year associated with self-reported.  It is the largest 
study of MBI to date by a significant margin and highlights the importance of assessing 
NPS, in the MBI framework, for testing association with cognitive decline.  More 
importantly, our study provides evidence that MBI identifies a group of people with a 
mean age of 62 who experienced subtle cognitive decline.  
 
The association found between working memory decline and MBI may be of particular 
relevance to preclinical AD.  Of the three test scores underlying the Working Memory 
factor, paired associates learning (PAL) and self-ordered search (which reflect 
visuospatial sketchpad elements of working memory) showed significantly higher 
declines in the MBI group over one year, perhaps reflecting preclinical AD working 
memory deficits (34).    We also demonstrate a strong association between attentional 
decline and MBI (as evidenced by the Sustained Attention, Attentional Intensity and 
Attentional Fluctuation composite measures).  While attentional deficits have been 
noted in early AD, attentional impairments including fluctuating attention are a 
common feature of dementia with Lewy bodies (35), and further work will be important 
to determine the predictive value of different MBI symptoms and different 
neuropsychological profiles for AD and DLB risk.   
 
Neuropsychiatric conditions are associated with cognitive deficits across the lifespan, 
and we must acknowledge that the etiology of MBI is still unclear (e.g. whether it is 
prodromal or a risk factor for dementia) and as such this finding may not wholly reflect 
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an underlying neurodegenerative process.  However, given the strong evidence of a 
relationship between MBI and dementia it is of significance that we have identified a 
cognitive phenotype which appear to accompany the MBI syndrome in individuals 
without clinically significant cognitive impairment.  There are three other reasons why 
our data support this relationship.  Firstly, in the current study we have removed 
anyone with a known history of psychiatric illness and evidence of MCI (including 
incident MCI), decreasing the likelihood of these conditions confounding our results.  
Secondly, the MBI-C is designed specifically to detect emergent neuropsychiatric 
disturbances which are relevant to dementia (either as risk factors or as preclinical or 
prodromal states).  Lastly, our analysis of the IQCCODE score showed a very strong 
relationship between reported memory problems and MBI grouping, suggesting a 
degree of independently measured memory complaint which is consistent with the 
results of the cognitive measures we report. 
 
Research must now move on to address whether MBI assessment can provide an 
additional approach to enrich clinical trial samples for disease modifying therapies (3) 
and potentially novel opportunities to prevent or delay progressive cognitive decline 
and dementia.  Firstly, deeper phenotyping (including fluid and imaging biomarkers, 
and longer term follow up) will be critical to establish whether the cognitive decline 
associated with MBI in this sample translates to MCI or dementia risk.   The advantage 
of the ISTAART-AA MBI criteria and the MBI-C are the generation of domain scores, 
which were designed and characterized a priori specifically for this purpose.  Work is 
underway to first establish the psychometric properties of the MBI-C in this sample 
which will feed into this work.   Only once these questions are answered can research 
progress to understanding whether MBI may provide an important potential target for 
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pharmacological and non-pharmacological interventions; establishing whether MBI is 
a modifiable risk factor or early preclinical/prodromal state will be an important avenue 
of research here. 
 
While previous studies have mapped NPS ratings on to the ISTAART diagnostic 
criteria to ascertain MBI (36, 37) our study used the MBI-C, which was designed, a 
priori, for pre-clinical populations. However, we relied upon a self-completed version 
of the MBI-C which may under-represent the social cognitive domain, resulting in an 
underestimation of risk. Moreover, the cut-point adopted was derived from an analysis 
of informant rated MBI-C, showing good sensitivity and specificity for clinically 
diagnosed MBI in clinical samples but our frequency estimate of 10% is comparable 
to a 14.2% frequency in a clinical sample of Spanish primary care patients that 
validated the current cut points (31, 38).  This estimate is considerably lower than other 
recent estimates of around 28% in a community sample (36) and 76.5% in a cognitive 
neurology clinic sample (37).  Both of these studies retrofitted the Neuropsychiatric 
Inventory items to map onto the ISTAART-AA criteria, and thus required any symptom 
to be present for only one month to satisfy MBI diagnostic criterion one - a more liberal 
threshold than the one used in this study. One can speculate that the lower MBI 
frequency in our study reflects a higher diagnostic specificity, eliminating false 
positives due to reversible factors and reactive states (11), and identifying a focused 
group for further assessment and workup, or intervention.   
 
We note the small effect sizes in this study and that the declines observed are not of 
a level that would be problematic to a given individual.  Moreover, very early markers 
will not by definition manifest as clinically significant declines in cognition.  However, 
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it is important to understand the analysis is of change over one year, in relatively young 
adults where cognitive changes are generally quite flat.  To give context to the effect 
sizes, the cognitive benefits of the major treatments for AD have an average effect 
size of 0.28 (39).  These subjects have signed up to participate in the study for 25 
years and thus the PROTECT study will continue to follow up these MBI groups to 
assess the progression of the cognitive trajectories.   The results demonstrate that the 
presence of early cognitive deficits can be sensitively detected in concert with the 
emergence of later life sustained NPS, measured by the MBI-C, an important finding 
which will engender new hypotheses about the etiology of MBI in the cognitively 
normal population. 
 
With regard to limitations, while this cognitive battery has provided detailed insight into 
the neuropsychological profile accompanying MBI and contains measures which are 
sensitive to AD (e.g. paired associates learning) we acknowledge that there are no 
measures of verbal episodic memory (e.g. word recall tests) which are also known to 
be sensitive to age-related cognitive decline.  Another limitation of this study is the 
self-selecting recruitment strategy which led to the overrepresentation of women and 
those with a higher education level.  Although we controlled for these variables in the 
analysis, some caution should be exercised before generalizing the findings to the 
wider population.   
 
 
In conclusion this study provides further evidence that MBI is a feature of cognitive 
aging in older adults without MCI or dementia. The MBI-C used in the general 
population could represent a cost effective and easily scalable tool for the early 
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indication of accelerated cognitive decline prior to the onset of MCI, in those with at 
most subjective cognitive decline.  We found a profile of declines in attention and 
working memory consistent with those seen in preclinical dementia, providing a strong 
impetus for future research to establish whether the routine inclusion of subclinical 
neuropsychiatric and neurobehavioral evaluations into preclinical disease risk 
modelling and epidemiological studies of cognitive aging is justified.   
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